Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
Public ClinicalTrials.gov record NCT05077969. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Virtual Phase 2 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Post-exposure Prophylaxis (PEP) for Newly-infected COVID-19 Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib. Each of these agents separately demonstrate clinical activity in mitigating COVID-19 disease symptoms or severity, and each of which appear to have separate and complementary mechanisms of action.
Study identification
- NCT ID
- NCT05077969
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 4 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 29, 2021 (Actual)
- Primary completion
- Jun 28, 2022 (Actual)
- Completion
- Jul 8, 2022 (Actual)
- Last update posted
- Jul 9, 2024
2021 – 2022
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Integrated Therapeutic Solutions USA, Inc. | Newport Beach | California | 92603 | — |
| Integrated Therapeutic Solutions USA, Inc. | Miami | Florida | 33126 | — |
| Integrated Health Solutions USA, Inc. | Atlanta | Georgia | 30363 | — |
| Integrated Therapeutic Solutions USA, Inc | Hazlehurst | Georgia | 31539 | — |
| Integrated Therapeutic Solutions USA, Inc. | Chicago | Illinois | 60611 | — |
| Integrated Therapeutic Solutions USA, Inc | Prospect | Kentucky | 40059 | — |
| Integrated Therapeutic Solutions USA, Inc | Frederick | Maryland | 21702 | — |
| Integrated Therapeutic Solutions USA, Inc | Gaithersburg | Maryland | 20878 | — |
| Integrated Therapeutic Solutions USA, Inc | Rockville | Maryland | 20850 | — |
| Integrated Therapeutic Solutions USA, Inc | Dearborn | Michigan | 48120 | — |
| Integrated Therapeutic Solutions USA, Inc. | Newark | New Jersey | 07102 | — |
| Integrated Therapeutic Solutions USA, Inc. | New York | New York | 10005 | — |
| Integrated Therapeutic Solutions USA, Inc. | Huntingdon | Pennsylvania | 16652 | — |
| Integrated Therapeutic Solutions USA, Inc. | Charleston | South Carolina | 29414 | — |
| Integrated Therapeutic Solutions USA, Inc. | Dallas | Texas | 75219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05077969, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 9, 2024 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05077969 live on ClinicalTrials.gov.